SCHEMBL3237604

SCHEMBL3237604

CC1CCCN(C(=O)c2ccc(C(=O)NCc3ccc(Cl)cc3)cc2)C1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 4/20 0.68
POLB P06746 1/20 0.63
DPP7 Q9UHL4 1/20 0.56
ALDH1A1 P00352 4/20 0.56
GAA P10253 1/20 0.56
HPGD P15428 1/20 0.56
RECQL P46063 1/20 0.54
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
MAPT P10636 2/20 0.53
RAB9A P51151 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
NPC1 O15118 1/20 0.53
HTT P42858 1/20 0.53
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3236002 0.93 GRM5 (0.58) GRM5POLBALDH1A1HPGDMEN1
SCHEMBL3263478 0.90 HPGD (0.60) GRM5POLBALDH1A1GAAHPGD
SCHEMBL3379917 0.89 GRM5 (0.57) GRM5POLBDPP7ALDH1A1GAA
SCHEMBL3235633 0.89 KMT2A (0.61) GRM5POLBALDH1A1GAAHPGD
SCHEMBL20394972 0.89 GAA (0.63) GRM5POLBALDH1A1GAAHPGD
SCHEMBL3237608 0.87 GRM5 (0.75) GRM5POLBDPP7ALDH1A1GAA
SCHEMBL14311713 0.86 GRM5 (0.85) GRM5POLBALDH1A1HPGDRECQL
SCHEMBL3264723 0.84 ALDH1A1 (0.55) ALDH1A1GAAHPGDMAPTRAB9A
SCHEMBL3259879 0.83 MAPT (0.70) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL3239708 0.82 HPGD (0.56) GRM5DPP7ALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 GRM5 1140/4885POLB 4525/4885DPP7 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.